Walleye Capital’s Dianthus Therapeutics DNTH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3M Buy
34,058
+16,177
+90% +$1.68M ﹤0.01% 2427
2026
Q2
$1.74M Sell
17,881
-135,704
-88% -$11.9M 0.01% 1634
2026
Q1
$12.9M Sell
153,585
-52,230
-25% -$3.02M 0.05% 313
2025
Q4
$8.48M Buy
205,815
+64,686
+46% +$2.51M 0.03% 761
2025
Q3
$5.55M Buy
141,129
+114,996
+440% +$2.94M 0.02% 867
2025
Q2
$487K Sell
26,133
-80,798
-76% -$1.52M ﹤0.01% 2656
2025
Q1
$1.94M Buy
106,931
+24,041
+29% +$530K 0.01% 1439
2024
Q4
$1.81M Buy
82,890
+52,890
+176% +$1.36M ﹤0.01% 1870
2024
Q3
$821K Buy
+30,000
New +$836K ﹤0.01% 2846
2024
Q2
– Sell
-190,266
Closed -$5.71M – 5675
2024
Q1
$5.71M Buy
+190,266
New +$4.14M 0.01% 1202
2022
Q2
– Sell
-2,584
Closed -$120K – 2454
2022
Q1
$120K Buy
2,584
+835
+48% +$45.6K ﹤0.01% 1692
2021
Q4
$124K Buy
+1,749
New +$176K ﹤0.01% 1615

Other funds holding DNTH

Walleye Capital's DNTH Position: Q3 2026 in Review

Walleye Capital increased its Dianthus Therapeutics (DNTH) stake by 90% in Q3 2026, buying an estimated $1.68M and bringing the position to 34,058 shares worth $3M. The position accounts for ﹤0.01% of the portfolio, ranked #2427.

Walleye Capital first reported a position in DNTH in Q4 2021 and has held it in 12 quarters since. The position peaked at $12.9M in Q1 2026. 274 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.

  • Walleye Capital held 34,058 shares of Dianthus Therapeutics worth $3M as of Q3 2026.
  • Walleye Capital bought 16,177 Dianthus Therapeutics shares in Q3 2026, an estimated $1.68M.
  • Dianthus Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #2427 holding.
  • Walleye Capital first reported a position in Dianthus Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Walleye Capital's Dianthus Therapeutics position peaked at $12.9M in Q1 2026.
  • 274 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.